Filing Flows › Comparisons › DTIL vs STRO
Precision Biosciences vs Sutro Biopharma: DTIL and STRO compared
Precision Biosciences is the larger company: $10.8M of revenue in its latest quarter (Q3 FY26) against $9.8M for Sutro Biopharma (Q2 2026). Precision Biosciences is growing faster (374× against -85% a year earlier). Precision Biosciences is more profitable, with an operating margin of -83.7% against -303.8%.
Where the money goes: DTIL and STRO
Precision Biosciences (DTIL) · Q3 FY26
Precision Biosciences, Q3 FY26: revenue $10.8M (374× year over year), operating margin -83.7%, net loss $18.4M, operating cash flow −$11.9M. The chart follows the revenue to costs, profit and cash.
Sutro Biopharma (STRO) · Q2 2026
Sutro Biopharma, Q2 2026: revenue $9.8M (-85% year over year), operating margin -303.8%, net loss $38.5M, operating cash flow −$38.3M. The chart follows the revenue to costs, profit and cash.
| Precision Biosciences (DTIL) | Sutro Biopharma (STRO) | |
|---|---|---|
| Latest quarter | Q3 FY26 | Q2 2026 |
| Revenue | $10.8M | $9.8M |
| Revenue growth, Y/Y | 374× | -85% |
| Operating margin | -83.7% | -303.8% |
| Net earnings | −$18.4M | −$38.5M |
| Net margin | -170.2% | -391.6% |
| Operating cash flow | −$11.9M | −$38.3M |
Questions
Which is bigger, Precision Biosciences or Sutro Biopharma?
Precision Biosciences is the larger company: $10.8M of revenue in its latest quarter (Q3 FY26) against $9.8M for Sutro Biopharma (Q2 2026).
Is Precision Biosciences or Sutro Biopharma growing faster?
Precision Biosciences is growing faster (374× against -85% a year earlier).
Which is more profitable, Precision Biosciences or Sutro Biopharma?
Precision Biosciences is more profitable, with an operating margin of -83.7% against -303.8%.
More: Precision Biosciences earnings · how Precision Biosciences makes money · Sutro Biopharma earnings · how Sutro Biopharma makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed May 5, 2026; 10-Q filed Aug 12, 2026). Fiscal quarters can end on different dates. Not investment advice.